Aclarion Implements 1-for-370 Reverse Stock Split to Maintain Nasdaq Listing

Aclarion, Inc., a healthcare technology company specializing in chronic low back pain diagnostics, has announced a significant corporate financial maneuver through a 1-for-370 reverse stock split of its common stock. The strategic action, approved by stockholders on December 31, 2024, aims to maintain the company's Nasdaq listing and improve its stock market positioning.

The reverse stock split will consolidate every 370 existing shares into a single share of common stock, with the change taking effect before market open on Wednesday, January 29, 2025. This move is primarily designed to help Aclarion meet Nasdaq's continued listing standards, specifically targeting an increase in the per-share price above the required $1.00 minimum bid price.

Shareholders will experience an automatic adjustment to their holdings, with brokerage accounts reflecting the new share count immediately. Stockholders holding physical stock certificates will receive instructions from Vstock Transfer, the company's transfer agent, regarding share exchange procedures.

The financial restructuring will dramatically reduce the company's outstanding shares from approximately 185 million to around 500,000. Importantly, the reverse stock split will not alter the total authorized number of shares or fundamentally change shareholders' proportional ownership in the company.

The split will comprehensively apply to all outstanding financial instruments, including warrants, stock options, and restricted stock units. Conversion and exercise prices for these securities will be proportionately adjusted to maintain their existing economic value.

For investors and market observers, this action signals Aclarion's commitment to maintaining its Nasdaq listing and potentially improving its market perception. By increasing the per-share stock price, the company hopes to attract more institutional investors and demonstrate financial stability.

Aclarion, known for its Nociscan platform that uses magnetic resonance spectroscopy to help physicians identify chronic low back pain sources, sees this financial maneuver as a strategic step in its ongoing corporate development.